<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088632</url>
  </required_header>
  <id_info>
    <org_study_id>XEO/SDS/01</org_study_id>
    <nct_id>NCT02088632</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for the Treatment of Trigeminal Neuralgia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IncobotulinumtoxinA (Xeomin®) is a neurotoxin which inhibits the release of certain chemicals&#xD;
      at the nerve terminals. It blocks cholinergic transmission at the neuromuscular junction by&#xD;
      inhibiting the release of acetylcholine from motor neurons. In addition it blocks the release&#xD;
      of Substance P (SP) and Calcitonin Gene Related Peptide (CGRP) from C fibers involved in pain&#xD;
      perception. This study is designed to see if Xeomin® is superior to placebo in the treatment&#xD;
      of medically refractory trigeminal neuralgia (TN). Subjects will be asked to maintain an&#xD;
      attack diary throughout the study. They will also be asked to attend 4 office visits; Visit&#xD;
      1- Screening Visit, Visit 2- Injection Visit, Visit 3- Follow-Up Visit and Visit 4- Final&#xD;
      Visit. At the end of the study the active (Xeomin®) and placebo groups will be compared to&#xD;
      see if one group had better relief than the other.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enrolled in a timely manner.&#xD;
  </why_stopped>
  <start_date type="Actual">March 14, 2014</start_date>
  <completion_date type="Actual">October 19, 2016</completion_date>
  <primary_completion_date type="Actual">June 11, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean number of attacks between active and placebo groups</measure>
    <time_frame>84 days</time_frame>
    <description>Patient evaluated at day 84. Mean daily number of attacks during baseline period (30days) will be compared to mean daily number of attacks for days 1-84 as recorded in patient diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mean intensity between placebo and control groups</measure>
    <time_frame>84 days</time_frame>
    <description>Patient evaluated at day 84. Mean daily intensity during baseline period (30days) will be compared to mean daily intensity for days 1-84 as recorded in patient diary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>Incobotulinumtoxina</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xeomin 25-100 units injected to chosen area one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Incobotulinumtoxina</intervention_name>
    <description>Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.</description>
    <arm_group_label>Incobotulinumtoxina</arm_group_label>
    <other_name>Xeomin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Normal saline is sterile sodium chloride without and preservatives.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>Normal Saline, sodium chloride, placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria&#xD;
&#xD;
          -  Age 18 - 75 yrs&#xD;
&#xD;
          -  Male or non-pregnant/non-lactating female&#xD;
&#xD;
          -  Subjects must have a mean attack frequency of at least 3 episodes/day of 4/10 pain&#xD;
&#xD;
          -  Use of adequate birth-control measures as determined by investigator for females of&#xD;
             child-bearing potential&#xD;
&#xD;
          -  Diagnosis of Classical trigeminal neuralgia (TN) using International Classification of&#xD;
             Headache Disorders (ICHD-2) criteria (see Appendix A in Protocol)&#xD;
&#xD;
          -  Subjects have given written informed consent prior to entering study&#xD;
&#xD;
          -  Subjects on a stable dose of concomitant preventive medications for treatment of TN&#xD;
             for at least 4 weeks prior to study entry and throughout the 12 week observation&#xD;
             period&#xD;
&#xD;
          -  Subjects who require &quot;rescue&quot; analgesic medication during the study will be allowed to&#xD;
             use their current (pre-study) opioid and/or non opioid analgesics as clinically&#xD;
             indicated (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, COX-2&#xD;
             inhibitors, topical analgesics).&#xD;
&#xD;
          -  Subjects will be prohibited from initiating any therapy with a new preventive&#xD;
             medication throughout the remainder of the study.&#xD;
&#xD;
          -  Subject must be willing and able to abstain from initiating an alternative therapy&#xD;
             (e.g., acupuncture, massage or physical therapy) for pain relief during the study.&#xD;
&#xD;
        (NOTE: subjects who are currently using alternative therapy for pain relief can be enrolled&#xD;
        if they are willing and able to maintain such therapy stable throughout the study.)&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:Exclusion Criteria&#xD;
&#xD;
          -  Symptomatic TN&#xD;
&#xD;
          -  Serious hepatic, respiratory, hematologic, cardiovascular or renal condition&#xD;
&#xD;
          -  Neurologic pain other than TN, with the exception of occasional migraine or&#xD;
             tension-type headaches. (&lt;4 headaches per month; &lt; 10 headache days/month)&#xD;
&#xD;
          -  Psychiatric or medical condition that might compromise participation in study, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Administration of any investigational drug within 30 days prior to screening&#xD;
&#xD;
          -  History of substance abuse/alcoholism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Silberstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson Headache Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigeminal Neuralgia</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

